DA
RVNC

Denali Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Denali Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,100
Closed -$12.6K – 517
2023
Q3 		$12.6K Hold
1,100
– – ﹤0.01% 361
2023
Q2 		$27.8K Hold
1,100
– – 0.01% 320
2023
Q1 		$35.4K Sell
1,100
-1,200
-52% -$37.4K 0.01% 251
2022
Q4 		$42.5K Sell
2,300
-2,200
-49% -$50.3K 0.02% 243
2022
Q3 		$122K Sell
4,500
-1,000
-18% -$20.3K 0.06% 159
2022
Q2 		$76K Sell
5,500
-1,000
-15% -$15.4K 0.03% 186
2022
Q1 		$127K Hold
6,500
– – 0.05% 179
2021
Q4 		$106K Buy
+6,500
New +$108K 0.04% 188

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Denali Advisors's RVNC Position: Q4 2023 in Review

Denali Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 1,100 shares — an estimated $12.6K sold.

Denali Advisors first reported a position in RVNC in Q4 2021 and held it in 8 quarters. The position peaked at $127K in Q1 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Denali Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Denali Advisors sold 1,100 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $12.6K.
  • Denali Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 8 quarters.
  • Denali Advisors's Revance Therapeutics, Inc. position peaked at $127K in Q1 2022.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Denali Advisors's 13F filing for Q4 2023, filed 19 Jan 2024.